Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-37 vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl binds to mu-opioid receptors, activating G-protein coupled receptor signaling, leading to inhibition of adenylate cyclase, decreased c AMP production, and modulation of ion channels (increased potassium efflux, decreased calcium influx). This results in reduced neuronal excitability, inhibition of nociceptive transmission, and altered pain perception. Additionally, fentanyl may interact with other opioid receptors (kappa, delta) with lower affinity.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of persistent, moderate to severe chronic pain in opioid-tolerant patients requiring around-the-clock opioid analgesia.,Management of breakthrough pain in cancer patients (immediate-release formulations).,Off-label: management of acute pain in emergency settings (e.g., trauma, procedures) under strict monitoring.,Off-label: management of postoperative pain (as part of multimodal analgesia).,Off-label: analgesia and sedation in mechanically ventilated patients (ICU setting).
Mild to moderate pain,Fever
Initial: 25 mcg/hour transdermal patch applied every 72 hours. Titrate based on opioid tolerance. For opioid-naive patients: 12 mcg/hour patch.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life 20-27 hours (range 13-42 h) after transdermal removal; due to continuous absorption from skin depot, effective half-life is longer during patch wear.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Fentanyl undergoes N-dealkylation and hydroxylation predominantly via hepatic CYP3A4 isoenzymes. Major metabolites include norfentanyl (inactive) and despropionylfentanyl (hydroxyfentanyl, inactive). Minor pathways involve CYP3A5 and possibly CYP2D6. Less than 10% of fentanyl is excreted unchanged in urine; most is eliminated as metabolites in urine and bile.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily renal: 75% as metabolites (mostly norfentanyl) and <10% unchanged drug. Fecal: 9% via biliary elimination.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 40% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
6 L/kg (range 4-7 L/kg), indicating extensive tissue distribution including brain and muscle.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Transdermal: approximately 92% of the dose reaches systemic circulation due to high permeability and first-pass avoidance.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
e GFR 30-89 m L/min: no initial dose adjustment but monitor closely; e GFR <30 m L/min: reduce starting dose by 50% or use 12 mcg/hour patch and titrate cautiously.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce starting dose by 50%; Child-Pugh C: consider alternative therapy; if used, start with 12 mcg/hour and monitor.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
For opioid-tolerant children ≥2 years: initiate with 25 mcg/hour patch if converting from ≥60 mg oral morphine equivalent. For opioid-naive children: not recommended. Dosing per weight: apply patch size based on prior opioid requirement (mcg/hour).
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
In patients >65 years: reduce starting dose by 50% (e.g., 12 mcg/hour for opioid-tolerant) and titrate slowly due to increased sensitivity and reduced clearance.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
FENTANYL EXPOSES USERS TO RISKS OF ADDICTION, ABUSE, AND MISUSE, WHICH CAN LEAD TO OVERDOSE AND DEATH. ASSESS EACH PATIENT’S RISK PRIOR TO PRESCRIBING. SERIOUS, LIFE-THREATENING, OR FATAL RESPIRATORY DEPRESSION MAY OCCUR WITH USE. MONITOR FOR RESPIRATORY DEPRESSION, ESPECIALLY DURING INITIATION OR FOLLOWING DOSE INCREASES. ACCIDENTAL EXPOSURE TO FENTANYL, ESPECIALLY IN CHILDREN, CAN RESULT IN FATAL OVERDOSE. CONCOMITANT USE OF CYP3A4 INHIBITORS MAY INCREASE FENTANYL PLASMA CONCENTRATIONS, POTENTIALLY RESULTING IN FATAL RESPIRATORY DEPRESSION. NEONATAL OPIOID WITHDRAWAL SYNDROME MAY OCCUR WITH PROLONGED USE DURING PREGNANCY. CYTOCHROME P450 3A4 INHIBITOR CONCOMITANT USE OR DISCONTINUATION OF CYP3A4 INDUCERS MAY RESULT IN FATAL OVERDOSE.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Respiratory depression: Life-threatening; monitor closely, especially during initiation and dose titration.,Addiction, abuse, and misuse: Increased risk with high doses and prolonged use.,Neonatal opioid withdrawal syndrome: Occurs with prolonged use during pregnancy; monitor neonates.,Interactions with CNS depressants (e.g., alcohol, benzodiazepines): Additive respiratory depression; avoid or reduce doses.,CYP3A4 interactions: Co-administration with CYP3A4 inhibitors (e.g., macrolides, azole antifungals) can increase fentanyl exposure; discontinue or reduce fentanyl dose. Co-administration with CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease efficacy.,Use in elderly or debilitated patients: Increased risk of respiratory depression; start with low doses and titrate slowly.,Use in patients with chronic pulmonary disease (e.g., COPD, cor pulmonale): Monitor respiratory function; may cause significant respiratory depression.,Use in patients with hepatic or renal impairment: Altered pharmacokinetics; monitor for adverse effects.,Use in patients with head injury or increased intracranial pressure: Avoid due to potential for respiratory depression and elevated CSF pressure; fentanyl may obscure neurological signs.,Use in patients with bradyarrhythmias (e.g., bradycardia): Fentanyl can decrease heart rate; use with caution.,Use in patients with convulsive disorders: May worsen seizures; monitor.,Use in patients with opioid addiction: May precipitate withdrawal; use only in opioid-tolerant patients.,Abrupt discontinuation: Can cause withdrawal symptoms; taper gradually.,Risk of severe hypotension: Especially in hypovolemic patients or those with compromised cardiovascular function.,Serotonin syndrome: Risk with concomitant use of serotonergic drugs (e.g., SSRIs, MAOIs); monitor for symptoms.,Adrenal insufficiency: Possible with prolonged opioid use; evaluate if symptoms develop.,Androgen deficiency: Possible with long-term use; consider if symptoms such as decreased libido, impotence, or amenorrhea occur.,Acute abdominal conditions: May obscure diagnosis or clinical course.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to fentanyl or any component of the formulation.,Significant respiratory depression (especially in unmonitored settings or absence of resuscitative equipment).,Acute or severe bronchial asthma in unmonitored settings.,Known or suspected gastrointestinal obstruction (including paralytic ileus).,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.,Opioid-naive patients (for formulation with strength > 12 mcg/hour, such as DURAGESIC-37, which is contraindicated in opioid-naive patients; initiation should be in opioid-tolerant patients).,Acute pain, including postoperative pain (except for short-term use in controlled settings).,Mild intermittent pain that can be managed with non-opioid analgesics.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid alcohol and grapefruit juice. Alcohol can potentiate CNS depression. Grapefruit juice may increase fentanyl levels via CYP3A4 inhibition.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
FDA Pregnancy Category C for chronic use; Category D for prolonged use or high doses at term. First trimester: risk of congenital anomalies unclear; may be associated with neural tube defects (case reports). Second/third trimesters: chronic use may cause fetal dependence, withdrawal, or respiratory depression. Near term: high doses can cause neonatal respiratory depression; use not recommended. Avoid during labor.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Fentanyl is excreted into breast milk; M/P ratio ~0.4-1.0. Relative infant dose ~2.5% of maternal weight-adjusted dose. Caution: potential for infant sedation, respiratory depression. Single doses acceptable; monitor infant for drowsiness. Chronic use not recommended due to accumulation.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pregnancy increases fentanyl clearance due to enhanced hepatic metabolism and increased renal blood flow; however, data limited. In third trimester, volume of distribution increases, possibly requiring higher doses for analgesia. Use lowest effective dose; avoid sustained-release forms. Monitor for maternal respiratory depression; may need to taper near term to prevent neonatal withdrawal.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
DURAGESIC-37 is a fentanyl transdermal system delivering 37 mcg/h. It is contraindicated in opioid-naïve patients due to risk of fatal respiratory depression. Apply to non-irritated, non-irradiated skin on upper torso. Do not cut or damage the patch. Monitor for signs of serotonin syndrome when used with serotonergic drugs. Disposal: fold patch sticky side together and flush down toilet.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Apply the patch to clean, dry, hairless skin on the chest, back, or upper arm. Do not use soap, alcohol, or oils before applying.,Do not cut or damage the patch; discard damaged patches.,Wash hands after handling the patch and avoid touching eyes.,Do not expose the patch to direct heat sources (heating pads, electric blankets, hot tubs, sunbathing) as this increases absorption.,Remove and fold the used patch with sticky sides together and flush immediately down the toilet.,Keep patches out of reach of children and pets.,Do not stop use suddenly; taper as directed to avoid withdrawal.,Report severe drowsiness, confusion, difficulty breathing, or slow heartbeat to a healthcare provider immediately.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-37 vs ACEPHEN, answered by our medical review team.
DURAGESIC-37 is a Opioid Analgesic that works by Fentanyl binds to mu-opioid receptors, activating G-protein coupled receptor signaling, leading to inhibition of adenylate cyclase, decreased c AMP production, and modulation of ion channels (increased potassium efflux, decreased calcium influx). This results in reduced neuronal excitability, inhibition of nociceptive transmission, and altered pain perception. Additionally, fentanyl may interact with other opioid receptors (kappa, delta) with lower affinity.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-37 and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-37 is: Initial: 25 mcg/hour transdermal patch applied every 72 hours. Titrate based on opioid tolerance. For opioid-naive patients: 12 mcg/hour patch.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-37 and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-37 is classified as Category C. FDA Pregnancy Category C for chronic use; Category D for prolonged use or high doses at term. First trimester: risk of congenital anomalies unclear; may be associated with neural t. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.